CADTH | Search
Current Filters
No filters applied.
Non-Medical Patient Transportation (Last Updated: Jul 23, 2021)
Peripherally Inserted Central Catheter Line Flow Rates for Patients Requiring Continuous or Intermittent Administration of Medications (Last Updated: Jul 23, 2021)
cemiplimab (Libtayo) (Last Updated: May 12, 2022)
Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Libtayo
Manufacturer:
Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
Submission Type:
Initial
Indications:
For the treatment of patients with locally advanced or metastatic basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor.
nivolumab (Opdivo) (Last Updated: Jul 23, 2022)
Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Opdivo
Manufacturer:
Bristol-Myers Squibb
Submission Type:
Initial
Indications:
In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.
COVID-19 Update (Last Updated: Jul 19, 2021)
CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time. Our COVID-19 Evidence Portal contains the latest COVID-19 information from CADTH and...
Project Line:
New at CADTH
bimekizumab (Bimzelx) (Last Updated: May 31, 2022)
Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Bimzelx
Manufacturer:
UCB Canada Inc.
Submission Type:
Initial
Indications:
For the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
selpercatinib (Retevmo) (Last Updated: Jul 13, 2022)
Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Retevmo
Manufacturer:
Eli Lilly Canada Inc.
Submission Type:
Initial
Indications:
Indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.
New at CADTH - July 2021 (Last Updated: Jul 13, 2021)
News and Events CADTH Symposium 2021 — Call for Abstract Reviewers The CADTH Symposium Team has received many excellent abstract submissions for the 2021 CADTH Symposium to be held November 2, 3, and...
Project Line:
New at CADTH
5-Aminolevulinic Acid Hydrochloride–Guided Surgical Resection of High-Grade Gliomas (Last Updated: Jul 13, 2021)
Project Line:
Reference List
Project Status:
Completed